Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogneic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.

This is a multi-center, open-label, Phase I/II study of obatoclax administered in combination with docetaxel in 3-week cycles to patients with relapsed or refractory Non-Small Cell Lung Cancer. Treatment may be administered on an outpatient basis. No investigation or commercial agents or therapies other than those described herein may be administered with the intent to treat the patient's malignancy. Supportive care measures including those directed at controlling symptoms resulting from Non-Small Cell Lung Cancer are allowed.

Inclusion Criteria:

• Pathological confirmation of Non-Small Cell Lung Cancer (NSCLC)
• Must have been previously treated with a single platinum-based chemotherapy regimen and shown evidence of disease progression; no further limitations
• Must have normal organ function
• Must be willing to submit to blood sampling for planned PK and PD analysis
• Must have the ability to understand and willingness to sign a written informed consent form

Exclusion Criteria:

• No other agents or therapies administered with the intent to treat malignancy
• Patients with prior exposure to obatoclax or docetaxel
• Uncontrolled, intercurrent illness
• Pregnant women and women who are breast feeding